3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Status
Recruiting
2
Sponsor Class
INDUSTRY
3
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
NET
2
Endocrine
2
Conditions
Neuroendocrine Tumors
2
Thymus Neoplasms
1
Interventions
pembrolizumab
603
Cyclophosphamide
545
Magnetic Resonance Spectroscopy
527
Radiotherapy
513
Specimen Handling
505
Nivolumab
411
Cisplatin
381
Carboplatin
369
Biopsy
305
Blood Specimen Collection
304
Radiosurgery
290
Paclitaxel
281
Gemcitabine
271
Surveys and Questionnaires
269
Standard of Care
267
fludarabine
263
Drug Therapy
263
Dexamethasone
263
Bevacizumab
252
venetoclax
251
Oxaliplatin
209
Capecitabine
199
Rituximab
198
Radiation
191
Ipilimumab
188
Fluorouracil
188
durvalumab
185
Doxorubicin
178
Etoposide
177
atezolizumab
172
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
OTHER
×
177Lu-octreotide, DOTA(0)-Tyr(3)-
×
1 year
×
Clear all
NCT05918302
2026-05-12
LEVEL
Grupo Espanol de Tumores Neuroendocrinos
Phase 3
Recruiting
170 enrolled
NCT05387603
2025-09-10
START-NET
Lund University Hospital
Phase 3
Recruiting
300 enrolled